By Billy Candra 
The pioneering research, spearheaded by a team at SickKids, addresses a formidable challenge inherent in brain cancer: the insidious nature of tumour development. By the time neurological symptoms manifest in a patient, brain tumours are frequently advanced and intricate, obscuring the fundamental cellular and molecular mechanisms that initially drove their growth. This complexity often renders the identification of primary drivers exceedingly difficult, complicating treatment strategies. Dr. Peter Dirks, a Senior Scientist in the Developmental, Stem Cell & Cancer Biology program and Chief of the Division of Neurosurgery at SickKids, has led a concerted effort to overcome this obstacle, specifically focusing on sonic hedgehog (SHH) medulloblastoma, which accounts for approximately 30% of all medulloblastoma cases. SHH medulloblastoma is characterized by aberrant activation of the SHH signaling pathway, crucial for normal embryonic development but oncogenic when dysregulated in later stages.
Unraveling the Mechanisms of Tumour Initiation and Recurrence
In a significant study recently published in Nature Communications, Dr. Dirks’ team identified a crucial protein responsible for reactivating dormant, or ‘sleeping,’ stem cells, thereby instigating SHH medulloblastoma tumour formation and driving its insidious regrowth following conventional treatments. This protein, identified as OLIG2, acts as a molecular switch, nudging quiescent neural stem cells into a proliferative state that ultimately leads to cancerous growth. The study’s core finding demonstrates that by effectively blocking OLIG2 and preventing these stem cells from awakening, a pivotal and potentially transformative treatment strategy emerges. This approach leverages sophisticated genomic methodologies in conjunction with rigorous functional experiments conducted in advanced preclinical models, showcasing a new frontier in targeted cancer therapy.
Dr. Dirks emphasized the profound implications of these findings, stating, "Our findings offer a novel strategy to target cancer stem cells, providing hope for more effective treatments against aggressive brain tumors." This statement underscores a shift in therapeutic philosophy, moving beyond merely debulking existing tumours to proactively intercepting the earliest stages of oncogenesis.
The Concept of Cancer Interception in Action
The research journey commenced with a meticulous examination of the cellular transitions that underpin the development of SHH medulloblastoma tumours. The team’s investigations revealed that both in the nascent stages of tumour development and critically, in the residual cellular populations remaining after standard therapeutic interventions, the OLIG2 protein plays a central role. It acts as the primary activator for ‘sleeping’ stem cells, compelling them to divide and proliferate, thereby forming the bulk of the tumour or initiating a relapse. Medulloblastoma, while having a relatively good prognosis compared to some other brain cancers (overall 5-year survival rates around 70-85% depending on risk stratification), still poses significant challenges, particularly concerning treatment-related morbidities and the persistent threat of recurrence, which dramatically lowers survival rates. The side effects of conventional treatments like radiation and chemotherapy can be particularly devastating for developing brains, leading to long-term cognitive, endocrine, and neurological impairments in child survivors.
Dr. Kinjal Desai, the first author of the study and a postdoctoral researcher in the Dirks lab, elaborated on the precision of their discovery: "There is order to how the cancer initiating stem cells undergo fate changes to form tumours. We can target an early transition event and intercept the entire process – essentially stopping the cancer in its earliest form." This insight highlights the potential for a new paradigm in oncology, where intervention occurs at the very genesis of the disease, preventing the cascade of events that lead to full-blown malignancy and recurrence.
During these critical cellular transitions, the researchers pinpointed a crucial window of opportunity during which tumour progression could be effectively blocked. Their strategy involved combining a previously established treatment regimen with a novel small molecule, CT-179. This molecule specifically targets and disrupts the function of the OLIG2 protein. By deploying CT-179, the research team successfully targeted the residual stem cells that often persist after conventional therapies, preventing their re-awakening and, crucially, averting tumour relapse in preclinical models. The ability to intercept these quiescent but dangerous cells represents a significant leap forward in addressing the root cause of many cancer recurrences.
Remarkably, the efficacy of CT-179 extended beyond preventing relapse. For early-stage SHH medulloblastoma, the administration of CT-179 was shown to prevent the initial formation of tumours altogether and significantly enhanced survival rates in the preclinical models. This dual capability – preventing both initiation and recurrence – positions CT-179 as a powerful candidate for future therapeutic development.
Broader Implications and Collaborative Validation
The findings from SickKids are further bolstered by a simultaneous publication in Nature Communications from collaborating institutions, including Children’s Healthcare of Atlanta and the QIMR Berghofer Medical Research Institute in Australia. These parallel studies provide independent validation of the core discovery, collectively showcasing the immense potential of this new treatment approach not only for SHH medulloblastoma but also for other highly aggressive and currently untreatable brain cancers, such as diffuse intrinsic pontine glioma (DIPG).
DIPG is a particularly devastating pediatric brain tumour, characterized by its location in the brainstem, making surgical resection impossible. The median survival for children diagnosed with DIPG is typically less than a year, and current treatments, primarily radiation, offer only temporary palliation without a cure. The possibility of applying the OLIG2-targeting strategy to DIPG opens a desperately needed avenue for therapeutic innovation for this uniformly fatal disease, offering a glimmer of hope to families facing unimaginable prognoses.
This recent study from the Dirks Lab complements their earlier foundational research published in Nature, which meticulously described the early stages of glioblastoma development. Glioblastoma, the most aggressive adult brain tumour, also presents significant challenges in treatment and recurrence, and understanding its early cellular dynamics is crucial for developing interception strategies. The consistent focus of the Dirks lab on understanding the earliest, most fundamental processes of brain tumour development underscores a strategic shift in cancer research towards prevention and early intervention.
The Road Ahead: From Lab to Clinic
While the immediate next steps will involve further rigorous preclinical validation and optimization, the ultimate goal is to translate these findings into clinical trials for patients. This will be particularly relevant for individuals who are currently being monitored for potential relapse after initial treatment, as well as for those at high genetic risk for developing SHH medulloblastoma. The Arthur and Sonia Labatt Brain Tumour Research Centre (BTRC) at SickKids, where the Dirks lab is a core component, is already a world-renowned hub for pediatric brain tumour research, poised to drive this translation.
Dr. Dirks expressed palpable excitement for the diagnostic potential inherent in this discovery. "At SickKids, we’re already genetically testing every child with cancer to inform their diagnosis and treatments – our study goes beyond genetic testing to precision biology," he remarked. This signifies a move from simply identifying genetic mutations to understanding and intervening in the precise biological pathways that drive cancer at a cellular level. "I am excited for a future where this ‘magic bullet’ for early treatment could be combined with diagnostic tests to potentially prevent the cancer from developing at all." This vision of a "magic bullet" combined with advanced diagnostics paints a future where cancer interception could become a reality, fundamentally altering the landscape of pediatric oncology. Imagine a scenario where children identified at high risk could receive targeted prophylactic treatment, effectively vaccinating them against a future brain tumour.
A Beacon of Hope for Pediatric Oncology
The implications of this research extend far beyond SHH medulloblastoma. It establishes a robust framework for identifying and targeting cancer stem cells, which are increasingly recognized as the architects of tumour initiation, progression, and therapeutic resistance across various cancer types. By elucidating a specific mechanism by which these stem cells are activated and demonstrating a precise method to inhibit that activation, the SickKids team has opened new avenues for understanding and combating cancer at its most fundamental level. This work underscores the critical importance of basic science research in unraveling complex biological puzzles, which ultimately paves the way for life-saving clinical applications.
The financial bedrock for such ambitious and long-term research is provided by a consortium of dedicated organizations. This study received vital funding from the Canadian Institutes of Health Research (CIHR), the Ontario Institute for Cancer Research, the Terry Fox Research Institute, the Canadian Cancer Society, Cancer Research UK, Stand Up to Cancer, Jessica’s Footprint Foundation, Hopeful Minds Foundation, b.r.a.i.n.child, Meagan’s Walk, the Garron Family Cancer Centre, the Bresler family, and the SickKids Foundation. Their unwavering commitment to advancing pediatric health and cancer research is indispensable for bringing such transformative discoveries from the laboratory bench to the patient’s bedside.
This discovery from SickKids represents not merely an incremental advance but a potential paradigm shift in the treatment and prevention of pediatric brain cancers. By focusing on cancer interception and precision biology, the research team offers a profound sense of hope for a future where the most common childhood malignant brain cancer, and potentially others, can be stopped before it ever truly begins, or prevented from ever returning, thus sparing countless children and their families from devastating diagnoses and arduous treatments.